INTRODUCTION
============

Intraductal papillary mucinous neoplasias (IPMNs) of the pancreas represent 25% of all cystic neoplasms,^[@bib1]^ with an assumed incidence of 0.8 per 100,000.^[@bib2]^ In 2006, the International Consensus guidelines raised the awareness of IPMN and for the first time defined management;^[@bib3]^ latterly, these guidelines have been updated.^[@bib4]^ IPMNs of both the main pancreatic duct (MD-IPMNs) and the branch ducts (BD-IPMNs) are often diagnosed incidentally by cross-sectional imaging^[@bib5],\ [@bib6],\ [@bib7]^ undertaken to investigate other pathology. All MD-IPMNs and BD-IPMNs with high-risk stigmata should be considered for resection. BD-IPMNs with "worrisome" stigmata require endoscopic ultrasound±fine needle aspiration. Simple BD-IPMNs even when in excess of 30 mm diameter can be entered into surveillance programs. However, there is no clear "best modality", no optimal interval, and no standard protocol of how to undertake this, with many institutional/national preferences. In addition, both serum tumor markers (carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19.9))^[@bib8]^ and cyst fluid analysis for cytology and/or tumor markers have been employed in identifying patients at risk of high-grade dysplasia or invasive cancer,^[@bib9]^ although again there is no universal practice.

As IPMN patients are at risk for developing pancreatic cancer, timely detection in high-risk groups is of paramount importance. Current guidelines that provide a framework for the management of IPMN are based on review of literature. More objective assessments in the form of systematic reviews with meta-analyses are limited.^[@bib10]^ Furthermore, the two published meta-analyses^[@bib11],\ [@bib12]^ primarily address only imaging characteristics (cyst size, mural nodule presence, and main pancreatic duct (MPD) dilation) predictive of malignancy.

The aims of this systematic review were: (1) to assess the diagnostic modality (computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)) with the best rate of detection for malignant change in IPMN and (2) the sensitivity and specificity of (i) risk features on imaging, i.e., mural nodule, cyst size, and main pancreatic duct dilation, (ii) cyst fluid tumor markers, (iii) serum tumor markers, and (iv) combination of parameters for detecting malignant transformation in IPMN.

METHODS
=======

Medline, Embase, and Web of Sciences databases were searched from November 2006 to March 2014. The start date of the searches was set to concur with the publication of the Sendai International Consensus Guidelines. Search terms were "intraductal papillary mucinous neoplasm" and "pancreas OR pancreatic OR pancrea\*." Inclusion criteria were retrospective and prospective studies dealing with IPMN. Exclusion criteria were case series of ≤10 patients and studies on cystic tumors where data were not separately available for patients with IPMN. Reference lists of selected studies were also reviewed for possible additional studies.

Two independent reviewers (A.S. and E.B.) assessed the abstract of every study identified by the search to determine eligibility. Blinding to source was not performed. Full articles were then selected for further assessment if the abstract suggested the study included patients with IPMN and the outcomes outlined before. If these criteria were unclear from the abstract, the full article was retrieved for clarification. Papers not meeting the inclusion criteria were excluded. Any disagreements were resolved by discussion. Following study selection, data extraction was undertaken by two independent assessors (either A.S. or E.B. and R.J.) and results compared. Data were extracted on the following parameters: patient demographics (age, gender), study period, imaging modality used, details on imaging of cyst size, presence of mural nodule, MPD size and cutoff used to consider MPD dilated, type of IPMN, cyst tumor marker levels/cutoff, serum tumor markers (CEA and CA19-9) levels/cutoff, management (resection with its details, or surveillance), and in resected patients details of histology (type of IPMN, and degree of dysplasia or invasive cancer).

The outcome measures were the sensitivity and specificity of a diagnostic modality/imaging risk feature for the detection of suspected high-grade dysplasia and invasive cancer (termed "malignancy"). Meta-analyses were carried out using a hierarchical summary receiver operator characteristic (HSROC) approach.^[@bib13]^ This approach calculates the position and shapes of the receiver operator curve for each diagnostic test and allows for variability both within and between studies. This approach allows for the estimated study sensitivity and specificity to be modeled jointly as opposed to analyzing each outcome separately and allows for correlation between the study outcomes to be accounted for. Diagnostic test was included as a covariate in the model as opposed to using different models for each test. This was to ensure summaries account for within-study variability as many studies report on more than one test. Each type of diagnostic test required a minimum of four observations to estimate all parameters. Both CT and MRI are merged into a single modality as there are not sufficient observations for pooled sensitivity/specificity estimates for each category separately. For the analysis of PET and CT/MRI features, only a few observations were available and models were simplified to produce parameter estimates by assuming constant variance in both the malignant and nonmalignant populations. Current international consensus guidelines for the management of IPMN^[@bib4]^ do not recommend endoscopic ultrasound (EUS) routinely, it being reserved for "worrisome cysts." Therefore, EUS findings rather than the use of it as a modality have been modeled.

Model summaries are presented in terms of sensitivity and specificity estimates with associated 95% credibility intervals (CIs) for each statistic individually. Graphical summaries are provided with the joint credibility interval for both sensitivity and specificity determined by the observed correlation between model parameters and the size set to contain 95% of the observed posterior estimates. The area under the curve (AUC), estimated using Monte Carlo integration are presented with associated 95% CI is used as a single measure to compare diagnostic tests.

Publication bias due to sample size was investigated by plotting the log diagnostic odds ratio (DOR) against the effective sample size.^[@bib14],\ [@bib15]^ Analyses were carried out using the statistical packages WinBUGS^[@bib16]^ and results compiled using R (version 3.01).^[@bib17]^ Parameters estimated were obtained via a Markov chain Monte Carlo) procedure (10,000 draws with a thin of 20 following burn in and convergence).

Assessment of study quality was done using the QUADAS-2 tool^[@bib18]^ utilizing Revman version 5.2 software.^[@bib19]^ Study heterogeneity is measured via means of Cochrane\'s Q statistic on the log diagnostic odds ratio for each modality separately. Sensitivity analyses are carried out to assess the effects of study quality and the effect of individual studies on the study results. The effect of study bias is assessed by removing all studies with at least one high-risk element via the QUADAS-2 tool. Influence measures for each study are carried out by fitting models with each study in turn omitted.

RESULTS
=======

A total of 481 eligible studies were identified, of which 51 studies met the inclusion criteria and 37 of these were incorporated into meta-analyses ([Figure 1](#fig1){ref-type="fig"}). Quality of studies included in meta-analyses is displayed in [Figure 2a](#fig2){ref-type="fig"}. Assessment of bias via a funnel plot is included in [Figure 2b](#fig2){ref-type="fig"} and show no evidence of publication bias (*P*=0.302).

The pooling of studies from the searches yielded 37 studies, incorporating 4,073 patients who were included in the meta-analyses ([Table 1](#tbl1){ref-type="table"}). A further 14 (1,156 patients) studies were included in the systematic review ([Table 2](#tbl2){ref-type="table"}), but not in the meta-analyses because of lack of extractable data.

The included studies were assessed for methodological quality. A summary of results is presented in [Figure 2a](#fig2){ref-type="fig"}. In accordance with the QUADAS-2 tool, each study was assessed for bias in four domains: patient selection, index test, reference standard, and flow/timing.^[@bib18]^

Five studies were deemed at high risk of selection bias because of concerns over the possible use of selective enrollment rather than a consecutive approach. The "blinding" of researchers to the reference standard was poorly documented, leading to an unclear assessment of test review bias in just a third of cases.^[@bib20]^ Similarly, the majority of studies did not clearly address the possibility of diagnostic review bias where prior knowledge of the index test could potentially influence interpretation of the reference standard.^[@bib20]^ In addition, relatively few studies reported the time interval between completion of the index test and collection of the reference standard, resulting in an unclear assessment of disease progression bias.^[@bib20]^ These areas of possible bias could lead to an overestimation of sensitivity and specificity of the index tests.^[@bib21]^ The applicability of the index tests, reference standard, and target population was generally high and thought to correlate well with the review question.

Histology based on resection was available in all included studies, except one. Sperti *et al.*^[@bib22]^ reported on 64 patients, with tissue diagnosis available in 47 subjects. In the analyses on CT/MRI and PET ability to detect malignancy, the analyses were restricted to the 47 patients who had tissue confirmation, as data for this subset were available. In the analyses on mural nodule, MPD dilation, and serum CA19-9, the entire study population was included as subset details were not available.

Imaging
-------

### CT vs. MRI

Two studies^[@bib23],\ [@bib24]^ directly compared CT with MRI in the diagnosis of IPMN ([Table 2](#tbl2){ref-type="table"}), but extractable data were only available in one study.^[@bib23]^ Waters *et al.*^[@bib23]^ retrospectively evaluated CT/magnetic resonance cholangiopancreatography data in 18 patients who had all been operated upon within 12 months of surgery. They found that secretin magnetic resonance cholangiopancreatography was superior to multidetector CT (16 and 64 slices) in identifying ductal connection, main duct involvement, or small cysts from side branch IPMN. Song *et al.*^[@bib24]^ studied 53 patients following surgery, of whom 31 were diagnosed as IPMN. MRI did not include secretin. One reader found the diagnostic accuracy for IPMN to be better for MRI than CT (0.995 vs. 0.875; *P*=0.10), but the other reader did not concur (0.932 vs. 0.850; *P*=0.059). Both readers found ductal communication to be significantly better delineated on MRI compared with CT.

### Prediction of malignancy by CT and/or MRI

Nine studies were included in the systematic review (295 patients),^[@bib22],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32]^ but meta-analyses could only be performed using data from four studies (159 patients);^[@bib22],\ [@bib25],\ [@bib26],\ [@bib27]^ Sperti *et al.*^[@bib22]^ evaluated 64 patients with helical CT (2.5 mm slices) and 60 patients with MRI/secretin-stimulated magnetic resonance cholangiopancreatography and reported the pooled results. Ogawa *et al.*^[@bib27]^ evaluated contrast-enhanced CT scans of 61 consecutive resections for IPMN using a multiphase scanner with either 4 or 16 detector rows and reconstruction with 5 mm thickness. The two radiologists were blinded to the findings at surgery/histology, and consensus of opinion was used to come to a conclusion. Tan *et al.*^[@bib26]^ employed 4- or 16-slice dual-phase CT with multiplanar volume reformations or curved reformations. Two radiologists blinded to the findings at surgery/histology reviewed the scans, and any difference of opinion was resolved by seeking input from a third radiologist. Hong *et al.*^[@bib25]^ used 16 or 64 detector CT, with two radiologists blinded to results of histology interpreting the scans independently.

The pooled sensitivity of CT/MRI to detect malignancy ([Table 3](#tbl3){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}) was 0.809 (95% CI 0.714--0.883) and the specificity was 0.762 (95% CI 0.654--0.851).

### Prediction of malignancy by PET

Systematic review and meta-analysis of 3 studies (106 patients) were undertaken. Hong *et al.*^[@bib26]^ used a PET scanner with axial field view of 15.7 cm, and maximal standardized uptake value (SUV) cutoff of 2.5. They opined that PET outperformed CT in detecting malignant IPMN. Tomimaru *et al.*^[@bib33]^ assessed different SUVmax levels to differentiate between benign and malignant IPMNs and found a value of 2.5 to be the best cutoff. A combination of mural nodule on CT and PET SUVmax of 2.5 lead to the best yield of detecting malignancy. Sperti *et al.*^[@bib22]^ performed fludeoxyglucose F 18 (18FDG) PET using a machine with field view of 16.2 cm, and concluded that PET (mean SUVmax 4.2; range 2.5--9) was more accurate than CT and MRI in distinguishing between benign and malignant IPMNs.

The pooled sensitivity of PET to detect malignancy ([Table 3](#tbl3){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}) was 0.968 (95% CI 0.900--0.995) and the specificity was 0.911 (95% CI 0.815--0.998).

### Prediction of malignancy by presence of mural nodule on imaging

A total of 21 studies (1,674 patients) evaluated the association between mural nodule and malignancy.^[@bib6],\ [@bib22],\ [@bib33],\ [@bib34],\ [@bib35],\ [@bib36],\ [@bib37],\ [@bib38],\ [@bib39],\ [@bib40],\ [@bib41],\ [@bib42],\ [@bib43],\ [@bib44],\ [@bib45],\ [@bib46],\ [@bib47],\ [@bib48],\ [@bib49],\ [@bib50],\ [@bib51]^ The pooled sensitivity was 0.69 (95% CI 0.585--0.793) and specificity was 0.798 (95% CI 0.722--0.862) ([Table 3](#tbl3){ref-type="table"} and [Figure 5](#fig5){ref-type="fig"}). Further analyses of the 14 studies (1,398 patients)^[@bib34],\ [@bib35],\ [@bib37],\ [@bib38],\ [@bib39],\ [@bib40],\ [@bib41],\ [@bib42],\ [@bib45],\ [@bib46],\ [@bib47],\ [@bib48],\ [@bib49],\ [@bib51]^ that dealt exclusively with BD-IPMN revealed a pooled sensitivity of 0.622 (95% CI 0.506--0.736) and specificity of 0.819 (95% CI 0.709--0.898) ([Table 4](#tbl4){ref-type="table"} and [Figure 6](#fig6){ref-type="fig"}).

There were variations between studies in the definition of this feature, and the imaging modality used (ultrasound, CT, MRI, endoscopic retrograde cholangiopancreatography, or EUS). Eighteen studies considered the presence of mural nodule as an at-risk feature, whereas in 4 studies the size of the mural nodule was considered. Two studies used a 5 mm cutoff,^[@bib34],\ [@bib35]^ one used 7 mm,^[@bib22]^ and another 10 mm.^[@bib41]^

### Prediction of malignancy by cyst size on imaging

The association of cyst size with malignancy was assessed in 16 studies (1,217 patients).^[@bib33],\ [@bib35],\ [@bib38],\ [@bib39],\ [@bib41],\ [@bib44],\ [@bib45],\ [@bib46],\ [@bib48],\ [@bib50],\ [@bib51],\ [@bib52],\ [@bib53],\ [@bib54],\ [@bib55],\ [@bib56]^ The pooled sensitivity was 0.682 (95% CI 0.575--0.789) and specificity was 0.574 (95% CI 0.43--0.702) ([Table 3](#tbl3){ref-type="table"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} online). Twelve of these studies (898 patients)^[@bib26],\ [@bib35],\ [@bib38],\ [@bib39],\ [@bib41],\ [@bib45],\ [@bib46],\ [@bib51],\ [@bib53],\ [@bib54],\ [@bib55],\ [@bib56]^ were limited to BD-IPMN, and here the pooled sensitivity was 0.671 (95% CI 0.527--0.804) and specificity was 0.574 (95% CI 0.413--0.722) ([Table 4](#tbl4){ref-type="table"} and [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). The majority of studies used 3 cm as cutoff (12 studies), whereas 2 cm was used in two studies^[@bib44],\ [@bib48]^ and 3.5 cm in one study.^[@bib56]^ Again, a variety of imaging methods (ultrasound, CT, MRI, endoscopic retrograde cholangiopancreatography, or EUS) were used.

### Prediction of malignancy by MPD dilation on imaging

A total of 14 studies (935 patients) assessed the prediction of malignancy on MPD dilation.^[@bib6],\ [@bib22],\ [@bib27],\ [@bib33],\ [@bib35],\ [@bib38],\ [@bib39],\ [@bib41],\ [@bib44],\ [@bib45],\ [@bib46],\ [@bib50],\ [@bib53],\ [@bib57]^ The pooled sensitivity was 0.614 (95% CI 0.471--0.746) and specificity was 0.687 (95% CI 0.564--0.799) ([Table 3](#tbl3){ref-type="table"} and [Figure 7](#fig7){ref-type="fig"}). Eight of these studies looked at BD-IPMN (679 patients)^[@bib35],\ [@bib38],\ [@bib39],\ [@bib41],\ [@bib45],\ [@bib46],\ [@bib53],\ [@bib57]^ and in this subgroup the pooled sensitivity was 0.508 (95% CI 0.317--0.697) and specificity was 0.747 (95% CI 0.539--0.911) ([Table 4](#tbl4){ref-type="table"} and [Figure 8](#fig8){ref-type="fig"}).

There were four different cutoff levels used to consider the MPD dilated. Two studies^[@bib22],\ [@bib27]^ used 10 mm as the cutoff, 7 mm was employed in four studies,^[@bib33],\ [@bib38],\ [@bib39],\ [@bib44]^ 6 mm in a further four,^[@bib41],\ [@bib45],\ [@bib46],\ [@bib57]^ and 5 mm in three studies.^[@bib35],\ [@bib50],\ [@bib53]^ The cutoff points of Manfredi *et al.*^[@bib6]^ were 5 mm in the head, 4 mm in the body, and 3 mm in the tail of pancreas.

Cyst fluid tumor markers
------------------------

Six studies^[@bib35],\ [@bib49],\ [@bib55],\ [@bib58],\ [@bib59],\ [@bib60]^ (270 patients) looked at cyst fluid tumor marker levels and their correlation with malignancy. All studies assessed cyst fluid CEA levels, and were assessed in meta-analysis. Only one study assessed CA 72--4 (ref. [@bib54]) and two CA19-9 (refs. [@bib50], [@bib54]) and hence were not included in the meta-analysis. The overall pooled sensitivity was 0.636 (95% CI 0.179--0.926) and specificity was 0.72 (95% CI 0.48--0.894) ([Table 3](#tbl3){ref-type="table"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). None of the studies provided data for the BD-IPMN subset.

Cyst fluid sample for tumor marker estimation was obtained at EUS in all but one study,^[@bib35]^ where the cyst fluid sample was taken at endoscopic retrograde cholangiopancreatography. Four different cutoff levels for cyst fluid CEA were used in the six studies. The most common one was 200 ng/ml employed in three studies.^[@bib38],\ [@bib53],\ [@bib54]^

Serum tumor markers
-------------------

Nine studies (975 patients)^[@bib8],\ [@bib22],\ [@bib35],\ [@bib38],\ [@bib40],\ [@bib53],\ [@bib56],\ [@bib57],\ [@bib61]^ looked at serum CA19-9 levels, and 6 of these studies (689 patients) evaluated BD-IPMNs.^[@bib35],\ [@bib38],\ [@bib40],\ [@bib53],\ [@bib56],\ [@bib57]^ The overall pooled sensitivity for all IPMN types was 0.380 (95% CI 0.156--0.634) and specificity was 0.903 (95% CI 0.846--0.947) ([Table 3](#tbl3){ref-type="table"} and [Figure 9](#fig9){ref-type="fig"}). The overall pooled sensitivity for BD-IPMN was 0.267 (95% CI 0.079--0.513) and specificity was 0.928 (95% CI 0.809--0.989) ([Table 4](#tbl4){ref-type="table"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). The majority of studies (*n*=7) used a cutoff value of 37 KU/l, though one study used 25 KU/l,^[@bib62]^ and in one study the cutoff value was not specified.^[@bib35]^

Seven studies (890 patients)^[@bib8],\ [@bib35],\ [@bib38],\ [@bib40],\ [@bib53],\ [@bib57],\ [@bib61]^ assessed serum CEA levels and 5 of these studies (662 patients) evaluated BD-IPMN.^[@bib35],\ [@bib38],\ [@bib40],\ [@bib53],\ [@bib57]^ The overall pooled sensitivity for all IPMN types was 0.169 (95% CI 0.074--0.321) and specificity was 0.933 (95% CI 0.867--0.972) ([Table 3](#tbl3){ref-type="table"} and [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). The overall pooled sensitivity for BD-IPMN was 0.129 (95% CI 0.047--0.286) and specificity was 0.943 (95% CI 0.824--0.99) ([Table 4](#tbl4){ref-type="table"} and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). Cutoff levels varied between studies, and in two studies^[@bib35],\ [@bib57]^ the cutoff was not specified. Three studies^[@bib8],\ [@bib61]^ used a cutoff of 5 μg/l, one study^[@bib53]^ used 4 μg/l and another study^[@bib38]^ 2.3 μg/l.

Combinations of predictors
--------------------------

Seven studies^[@bib26],\ [@bib27],\ [@bib35],\ [@bib50],\ [@bib54],\ [@bib56],\ [@bib63]^ encompassing 400 patients pooled combinations of parameters to assess their ability to predict malignancy. The overall pooled sensitivity was 0.743 (95% CI 0.542--0.9) and specificity was 0.906 (95% CI 0.782--0.963) ([Table 3](#tbl3){ref-type="table"} and [Figure 10](#fig10){ref-type="fig"}).

Salvia *et al.*^[@bib56]^ considered the presence of mural nodule or thick walls and septae as suspicious radiological features, Tan *et al.*^[@bib26]^ combined mural nodule and thick septae, and Woo *et al.*^[@bib54]^ combined mural nodule and thick wall. Fritz *et al.*^[@bib63]^ used serum CA19-9 and serum CEA in the combination. Hirono *et al.*^[@bib35]^ employed a combination of mural nodule \>5 mm present on EUS/CT, and raised CEA in pancreatic juice obtained at endoscopic retrograde cholangiopancreatography. Ogawa *et al.*^[@bib27]^ used a combination of the presence of mural nodule and abnormal attenuating area in surrounding pancreas parenchyma. Two different combinations were assessed by Takeshita *et al.*,^[@bib50]^ one being MPD dilation and presence of mural nodule, and the other MPD dilation and cyst size \>3 mm. Data were not extractable on the BD-IPMN subset.

Based on these studies the most valuable combination for estimating malignant transformation would appear to be mural nodule (pooled sensitivity 0.690; 95% CI 0.585--0.793) and serum CA19-9 (pooled specificity 0.903; 95% CI 0.846--0.947).

Sensitivity analysis
--------------------

Results of the sensitivity analysis are included in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}. Influence measures for each study are given in [Supplementary Figure S7](#sup1){ref-type="supplementary-material"}. They show that the effect of each individual study is relatively small. The biggest effects are observed for diagnostic categories with the fewest data items and greater variability such as the CEA category; however, even here the effects of each study are small. Further sensitivity analyses are carried out that remove any study that is attributed a "high-risk" score for any component of the QUADAS-2 tool. A total of 11 studies are removed for this analysis and the results are included in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. The results obtained here do not differ substantially from those presented in [Table 3](#tbl3){ref-type="table"}.

DISCUSSION
==========

We have adopted a novel approach by using HSROC curves to compare variations in diagnostic threshold; this is commonly demonstrated when different definitions are used in studies for features found in imaging and tumor markers. The HSROC method also allows for both within- and between-study variability of sensitivity and specificity (i.e., random effects), and their possible correlations as well as the precision of these estimates within a study.^[@bib64]^ The two existing meta-analyses^[@bib11],\ [@bib12]^ used DORs to pool studies. The drawback with this approach is the inability of DOR to simultaneously deal with two outcomes, i.e., sensitivity and specificity. In addition, DORs are difficult to interpret clinically, and in practice DOR is reasonably constant regardless of the diagnostic threshold.^[@bib65]^

This work has reviewed the risk of malignant transformation in all IPMNs, and wherever possible, the BD-IPMN subset; it is restricted to studies subsequent to the Sendai guidelines publication. Although Anand *et al.*^[@bib12]^ also included all IPMN types, no subgroup analysis was performed, whereas the review by Kim *et al.*^[@bib11]^ was confined to BD-IPMNs; in reality, only 9 of 23 studies dealt with BD-IPMNs. On quality assessment, the majority of studies in our review had high to unclear risk of bias in terms of patient selection, index test used, and flow/ timing, but had low risk of bias for features dealing with applicability concerns. This is because all but one study was retrospective. In contrast to the meta-analyses of Kim *et al.*^[@bib11]^ that concluded that all their included (*n*=23) studies satisfied ≥5 of the total 7 points on quality assessment, in our study just 16% (6/37) met ≥5 points. Anand *et al.*^[@bib12]^ did not comment on study quality.

PET shows the most promise as a technique in determining malignant transformation within IPMN; accepting that there are only three reports and the overall sample size is small. The study by Hong *et al.*^[@bib25]^ noted that SUVmax was significantly higher in malignant IPMNs, with a mean of 6.7 and s.d. of 3.6 compared with benign IPMN (mean 2.1 and s.d. 1). Tomimaru *et al.*^[@bib33]^ assessed different SUVmax levels to differentiate between benign and malignant IPMNs; importantly, a correlation between the grade of dysplasia, with high-grade dysplastic lesions having higher SUVmax than low/moderate-grade dysplasia, was noted. Overall, a combination of mural nodule on CT and PET SUVmax of 2.5 led to the best yield of detecting malignancy. This was supported by Sperti *et al.*^[@bib22]^ who concluded that PET (mean SUVmax 4.2; range 2.5--9) was more accurate than CT and MRI in distinguishing between benign and malignant IPMNs. Notes of caution must be raised: when interpreting PET scan, SUV can be affected by tumor size, patient weight, and blood glucose level, as also the potential of differing results between different scanners. False positive values can also occur in the presence of acute and chronic pancreatitis, and if endoscopic interventions on the pancreas are performed before PET. Overall, the sensitivity, specificity, and AUC (95% CI) for PET was 0.968 (0.900--0.995), 0.911 (0.815--0.998), and 0.985 (0.949--0.998), [Table 3](#tbl3){ref-type="table"}. We await the report of the ongoing (closed to recruitment) PET-PANC trial (<http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=8166>) that has evaluated the role of PET CT in pancreatic cancer.

The benefit of CT vs. MRI in predicting malignancy within IPMN was not confirmed by this systematic review; however, these technologies have advanced dramatically over time,^[@bib66],\ [@bib67]^ such that modern contrast agents (and secretin stimulation) provide better images than earlier techniques.^[@bib68],\ [@bib69],\ [@bib70]^ Overall the sensitivity, specificity, and AUC (95% CI) for CT/MRI are 0.809 (0.714--0.883), 0.762 (0.654--0.851), and 0.856 (0.778--0.915). Although analysis of CT vs. MRI was not possible, these data support a trial of direct comparison of modern contrast-enhanced CT vs. secretin-stimulated magnetic resonance cholangiopancreatography.

We did not specifically look at EUS as it is not used for first-line imaging, but instead employed to evaluate in greater detail suspicious features reported on screening investigations.

In our meta-analyses, the presence of a mural nodule on cross-sectional imaging had good specificity and sensitivity for predicting malignancy in all IPMNs (sensitivity 0.69; specificity 0.798; AUC 0.819, see [Table 3](#tbl3){ref-type="table"}), as well as in BD-IPMN (sensitivity 0.622; specificity 0.819; AUC 0.749, see [Table 4](#tbl4){ref-type="table"}), and performed the best compared with all other parameters, with the exception of when parameters were combined.

We have demonstrated poor performance of cyst fluid CEA as a discriminator between benign and malignant IPMNs. The utility of a raised CEA only identifies the presence of mucin and the implied risk of malignant transformation of mucinous lesions (IPMN or mucinous neoplasms). Concentrating on studying novel molecular/proteomic markers in cyst fluid may shed light on a better predictor.

Serum tumor markers were highly specific but poor on sensitivity in meta-analyses of all IPMN and BD-IPMN subsets. However, serum CA19-9 was significantly raised in patients with invasive cancer, but not high-grade dysplasia,^[@bib8],\ [@bib61]^ as also CEA.^[@bib8]^ The majority of studies either combined HGD with invasive cancer^[@bib35],\ [@bib38],\ [@bib53],\ [@bib57]^ or the numbers were too small to draw a meaningful conclusion.^[@bib22],\ [@bib40],\ [@bib56]^ This implies, from the available evidence, that CA19-9 is highly specific for invasive cancer in IPMN, and would be a useful adjunctive tool. Discovery of more sensitive biomarkers that can discriminate malignant transformation are needed.

Combinations of parameters performed the best on meta-analyses, having the highest pooled sensitivity, specificity 0.743 (0.542--0.900); 0.906 (0.782--0.963); and AUC 0.907 (0.701--0.999), for detection of malignancy within IPMN; although several combinations were used across the eight studies. Mural nodule presence along with another parameter were assessed in six of these studies. Correa-Gallego *et al.*^[@bib71]^ have developed a preoperative nomogram using data on 219 resected IPMN. Male gender, a history of weight loss and previous malignancy, and presence of a solid component on imaging conferred increased risk of malignancy in patients with main/mixed duct IPMN. In BD-IPMN, factors that raised the risk of malignancy were a history of weight loss, presence of a solid component of imaging, and cyst size. Future prospective studies assessing multiple parameters and using externally validated predictive nomograms to ascertain risks may be a way forward.

The model used to synthesize the data, while allowing for study heterogeneity, did not take any direct account of the different cutoff values or definitions used for each modality because of the large variability that was observed. Although study heterogeneity was not highlighted as a main cause for most modality, increasing standards of reporting would allow for a more concise review of the data and would be of clinical interest.

In conclusion, these systematic review/meta-analyses suggest elevated serum CA19-9 levels and presence of mural nodule to be the stand-alone features strongly correlated with malignancy. Recommending one modality over another for diagnosis is difficult based on the available literature, and although PET scanning has promise, it requires evaluation in larger studies with improved quality.

Future directions
-----------------

In future, prospective longitudinal studies using standardized imaging (CT/MRI) with uniform definitions for risk features to allow comparability between studies are needed. Comparative studies evaluating CT vs. MRI, and PET vs. CT/MRI, may help shed light on the optimal imaging approach. Combining risk features on history, imaging, and tumor markers in both serum and cyst fluid, as well as investing in the efforts to discover/validate novel biomarkers, may help refine the at-risk group, improving the specificity of current guidelines and sparing unnecessary surgery for those with low- to moderate-grade dysplasia.

Study Highlights
================
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![Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of study selection.](ctg201560f1){#fig1}

![Assessments of study quality and bias. QUADAS-2 quality assessment of studies included in (**a**) meta-analyses and (**b**) bias.](ctg201560f2){#fig2}

![Hierarchical summary receiver operator characteristic (HSROC) curve of prediction of malignancy by computed tomography/magnetic resonance imaging (CT/MRI). Note that the numbers represent the studies detailed in table (inset in figure). The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval.](ctg201560f3){#fig3}

![Hierarchical summary receiver operator characteristic (HSROC) curve of prediction of malignancy by positron emission tomography (PET) scan. Note that the numbers represent the studies detailed in table (inset in figure). The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval.](ctg201560f4){#fig4}

![Hierarchical summary receiver operator characteristic (HSROC) curve of prediction of malignancy by mural nodule on imaging (all intraductal papillary mucinous neoplasia (IPMN) types). Note that the numbers represent the studies detailed in table (inset in figure). The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval.](ctg201560f5){#fig5}

![Hierarchical summary receiver operator characteristic (HSROC) curve of prediction of malignancy by mural nodule on imaging for branch duct intraductal papillary mucinous neoplasia (IPMN). Note that the numbers represent the studies detailed in table (inset in figure). The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval.](ctg201560f6){#fig6}

![Hierarchical summary receiver operator characteristic (HSROC) curve of prediction of malignancy by main pancreatic duct (MPD) dilation on imaging (all intraductal papillary mucinous neoplasia (IPMN) types). Note that the numbers represent the studies detailed in table (inset in figure). The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval.](ctg201560f7){#fig7}

![Hierarchical summary receiver operator characteristic (HSROC) curve of prediction of malignancy by main pancreatic duct (MPD) dilation on imaging for branch duct intraductal papillary mucinous neoplasia (IPMN). Note that the numbers represent the studies detailed in table (inset in figure). The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval.](ctg201560f8){#fig8}

![Prediction of malignancy by serum carbohydrate antigen 19-9 (CA19-9) levels (all intraductal papillary mucinous neoplasia (IPMN) types). Note that the numbers represent the studies detailed in table (inset in figure). The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval.](ctg201560f9){#fig9}

![Prediction of malignancy by combinations of predictors. Note that the details of the different combinations used in each study are displayed in column 2 of the table inset into the figure. Each letter represent the following characteristic: A, mural nodule; B, thick wall and/or septae; C, MPD dilation; D, cyst size \>3 mm; E, serum CA19-9 and CEA; F, raised cyst fluid CEA; G, abnormal area in pancreas. The numbers represent the studies detailed in the table. The black circles represent the individual study estimate, and vary based on study size. The blue circle stands for the overall estimate pooling all studies, and the dotted blue line indicates the 95% credibility interval. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; MPD, main pancreatic duct.](ctg201560f10){#fig10}

###### Studies included in meta-analyses

  **First author**                                  **Year**    **Study period**  **Number of patients**   **Median age in years**   **Number of males**   **Types of IPMN (number)**                                                                            **Number resected**
  ------------------------------------------------- ---------- ------------------ ------------------------ ------------------------- --------------------- ----------------------------------------------------------------------------------------------------- ---------------------
  Sahora^[@bib52]^                                  2013           1995--2012     563                      67                        232                   BD (563)                                                                                              226
  Shimizu^[@bib34]^ [a](#t1-fn2){ref-type="fn"}     2013           1996--2011     310                      67.1 (mean)               181                   MD (51), mixed (57), BD (202)                                                                         310
  Fritz^[@bib63]^                                   2012           2004--2010     123                      NA                        NA                    BD (123)                                                                                              123
  Hirono^[@bib35]^                                  2012           1999--2011     134                      69 (mean)                 74                    BD (134)                                                                                              134
  Kurihara^[@bib36]^                                2012           2003--2007     22                       68 (mean)                 14                    MD (6), BD (16)                                                                                       22
  Ohno^[@bib37]^                                    2012           2001--2009     142                      65 (mean)                 77                    BD (142)                                                                                              30
  Ohtsuka^[@bib38]^                                 2012           1990--2010     138                      67 (mean)                 83                    MD (39), BD (99)                                                                                      138
  Akita^[@bib39]^                                   2011           1992--2007     38                       63 (mean)                 20                    BD (38)                                                                                               38
  Cone^[@bib58]^                                    2011           2001--2009     52                       65 (mean)                 24                    NA                                                                                                    52
  Fritz^[@bib8]^                                    2011           2004--2008     142                      NA                        82                    MD (16), mixed (75), BD (51)                                                                          142
  Hwang^[@bib40]^ [a](#t1-fn2){ref-type="fn"}       2011           1994--2008     237                      63 (mean)                 137                   BD (237)                                                                                              247
  Maguchi^[@bib41]^ [a](#t1-fn2){ref-type="fn"}     2011         Not specified    349                      66                        170                   BD (349)                                                                                              29
  Xu^[@bib61]^                                      2011           1999--2008     86                       62 (mean)                 62                    NA                                                                                                    86
  Arikawa^[@bib42]^                                 2010           2003--2008     25                       65.2 (mean)               20                    BD (25)                                                                                               25
  Hong^[@bib25]^                                    2010           2005--2009     31                       65 (mean)                 15                    MD (NA), BD (49)                                                                                      31
  Ingkakul ^[@bib57]^                               2010           1987--2008     200                      NA                        108                   BD (200)                                                                                              200
  Jing^[@bib43]^                                    2010           1993--2007     39                       55 (mean)                 39                    MD (11), mixed (4), BD (24)                                                                           39
  Liu^[@bib44]^                                     2010           2001--2008     25                       61                        14                    MD (5), mixed (13), BD (7)                                                                            25
  Mimura^[@bib45]^                                  2010           1998--2009     82                       69                        49                    MD (39), BD (43) (did not consider mixed IPMN; classified based on predominant type into MD and BD)   82
  Sadakari^[@bib53]^                                2010           1987--2008     73                       66                        48                    BD (73)                                                                                               73
  Tomimaru^[@bib33]^                                2010           2006--2008     29                       NA                        13                    MD (3), mixed (13), BD (13)                                                                           29
  Correa-Gallego^[@bib59]^                          2009               NA         72                       NA                        NA                    NA                                                                                                    NA
  Manfredi^[@bib6]^                                 2009           2001--2005     51                       62 (mean)                 32                    MD (29), mixed (22)                                                                                   Nil
  Nagai^[@bib46]^                                   2009           1984--2007     84                       63                        48                    BD (84)                                                                                               84
  Ohno^[@bib47]^                                    2009           2001--2007     87                       67 (mean)                 53                    MD (14), mixed (25), BD (48)                                                                          87
  Tan^[@bib26]^                                     2009           2005--2008     20                       62 (mean)                 11                    MD (3), mixed (12), BD (5)                                                                            20
  Woo^[@bib54]^                                     2009           1998--2005     190                      63(mean)                  111                   BD (190)                                                                                              85
  Jang^[@bib48]^ [a](#t1-fn2){ref-type="fn"}        2008           1993--2006     138                      61 (mean)                 87                    BD (138)                                                                                              138
  Maire^[@bib60]^                                   2008           1994--2006     41                       64                        16                    MD (2), mixed (26), BD (13)                                                                           41
  Ogawa^[@bib27]^                                   2008           2000--2006     61                       64.9 (mean)               39                    MD (NA), mixed (NA), BD (49)                                                                          61
  Pitman^[@bib49]^                                  2008           1992--2006     20                       68 (mean)                 11                    BD (20)                                                                                               18
  Takeshita^[@bib50]^                               2008           2002--2006     46                       65 (mean)                 28                    BD (46), mixed IPMN also grouped under BD                                                             46
  Tang^[@bib55]^                                    2008           1995--2006     31                       66.6 (mean)               19                    BD (31)                                                                                               31
  Pais^[@bib62]^                                    2007           1992--2006     74                       65                        38                    MD (21), mixed (35), BD (18)                                                                          74
  Rodriguez^[@bib51]^ [a](#t1-fn2){ref-type="fn"}   2007           1990--2005     145                      67                        62                    BD (145)                                                                                              145
  Salvia^[@bib56]^ [b](#t1-fn3){ref-type="fn"}      2007           2000--2003     109                      64                        45                    BD (109)                                                                                              25
  Sperti^[@bib22]^                                  2007           1999--2005     64                       64 (mean)                 33                    MD (28), BD (36)                                                                                      42

BD, branch duct; IPMN, intraductal papillary mucinous neoplasia; MD, main duct, NA, not available.

Multicentric study.

Prospective study.

###### Studies included in systematic review only

  **First author**     **Year**    **Study period**  **Number of patients**    **Median age in years**  **Number of males**    **Types of IPMN (number)**  **Number resected**
  -------------------- ---------- ------------------ ------------------------ ------------------------- --------------------- ---------------------------- ---------------------
  Bae^[@bib72]^        2012           1995--2010     194                                 63             116                             BD (194)           52
  Kang^[@bib73]^       2011           2000--2009     201                              63 (mean)         111                             BD (201)           35
  Uehara^[@bib74]^     2011               NA         100                                 65             53                              BD (100)           1
  Zhang^[@bib28]^      2011           2004--2009     36                               64 (mean)         26                              BD (36)            36
  Kanno^[@bib75]^      2010           1995--2007     159                              69 (mean)         96                              BD (159)           44
  Yamada^[@bib29]^     2010           1997--2004     20                               72 (mean)         11                     MD (3), mixed (16), BD (1)  20
  Salvia^[@bib76]^     2009           1990--2006     131                                 67             52                              BD (131)           10
  Yoon^[@bib30]^       2009           2004--2007     21                               69 (mean)         7                         Mixed (10), BD (11)      21
  Manfredi^[@bib31]^   2008           2001--2006     26                               67 (mean)         10                              BD (16)            \-
  Rautou^[@bib77]^     2008           1999--2005     121                                 63             25                              BD (121)           2
  Tanno^[@bib78]^      2008           1990--2006     82                                  68             57                              BD (82)            7
  Yamada ^[@bib32]^    2008           1997--2004     16                               65 (mean)         13                     MD (1), mixed (8), BD (7)   16
  Waters^[@bib23]^     2008           1991--2006     18                                  66             7                      MD (1), mixed (4), BD (13)  18
  Song^[@bib24]^       2007           2002--2006     31                             Not detailed        NA                            Not detailed         31

BD, branch duct; IPMN, intraductal papillary mucinous neoplasia; MD, main duct, NA, not available.

###### Imaging and tumor marker characteristics suggestive of malignancy in IPMN (all types)

  **Characteristic**                    **Sensitivity (95%CI)**   **Specificity (95% CI)**   **Area under the curve (95% CI)**   **Q-test for heterogeneity**
  ------------------------------------- ------------------------- -------------------------- ----------------------------------- ------------------------------
  Presence of risk features on CT/MRI   0.809 (0.714--0.883)      0.762 (0.654--0.851)       0.856 (0.778--0.915)                5.24 (0.15)
  Presence of risk features on PET      0.968 (0.900--0.995)      0.911 (0.815--0.998)       0.985 (0.949--0.998)                7.82 (0.02)
  Mural nodule presence                 0.69 (0.585--0.793)       0.798 (0.722--0.862)       0.819 (0.719--0.925)                21.7 (0.36)
  Main pancreatic ductal dilation       0.614 (0.471--0.746)      0.687 (0.564--0.799)       0.702 (0.596--0.838)                7.48 (0.88)
  Cyst size \>3 cm                      0.682 (0.575--0.789)      0.574 (0.43--0.702)        0.657 (0.575--0.766)                17.14 (0.004)
  Cyst fluid elevated CEA levels        0.636 (0.179--0.926)      0.72 (0.48--0.894)         0.843 (0.481--0.997)                22.41 (0.1)
  Elevated serum CEA levels             0.169 (0.074--0.321)      0.933 (0.867--0.972)       0.691 (0.375--0.996)                3.24 (0.78)
  Elevated serum CA19-9 levels          0.38 (0.156--0.634)       0.903 (0.846--0.947)       0.729 (0.651-- 0.792)               6.05 (0.42)
  Combinations                          0.743 (0.542--0.9)        0.906 (0.782--0.963)       0.907 (0.701--0.999)                8.34 (0.3)

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; CT/MRI, computed tomography/magnetic resonance imaging; IPMN, intraductal papillary mucinous neoplasia; PET, positron emission tomography.

Risk features on imaging were presence of mural nodule/septation, cyst size \>3 cm, main pancreatic duct dilation, and uptake on PET.

###### Imaging and tumor marker characteristics suggestive of malignancy in BD-IPMN

  **Characteristic**                **Sensitivity (95% CI)**   **Specificity (95% CI)**   **Area under the curve (95% CI)**   **Q-test for heterogeneity**
  --------------------------------- -------------------------- -------------------------- ----------------------------------- ------------------------------
  Mural nodule presence             0.622 (0.506--0.736)       0.819 (0.709--0.898)       0.749 (0.644--0.888)                14.79 (0.32)
  Main pancreatic ductal dilation   0.508 (0.317--0.697)       0.747 (0.539--0.911)       0.629 (0.507--0.815)                4.05 (0.99)
  Cyst size \>3 cm                  0.671 (0.527--0.804)       0.574 (0.413--0.722)       0.662 (0.563--0.783)                8.43 (0.75)
  Elevated serum CEA levels         0.129 (0.047--0.286)       0.943 (0.824--0.99)        0.530 (0.241--0.987)                0.93 (0.97)
  Elevated serum CA19-9 levels      0.267 (0.079--0.513)       0.928 (0.809--0.989)       0.724 (0.378--1.000)                3.4 (0.64)

BD-IPMN, branch duct intraductal papillary mucinous neoplasia; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; PET, positron emission tomography.
